Difference between revisions of "Hairy cell leukemia"
Jump to navigation
Jump to search
m |
(formatting) |
||
| Line 3: | Line 3: | ||
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | ||
| − | {{TOC limit|limit= | + | {{TOC limit|limit=2}} |
==Cladribine (Leustatin)== | ==Cladribine (Leustatin)== | ||
| − | ===Regimen #1 | + | ===Regimen #1, Chadha, et al. 2005=== |
| − | *[[Cladribine (Leustatin)]] 0.1 mg/kg/day IV continuous infusion on days 1 | + | *[[Cladribine (Leustatin)]] 0.1 mg/kg/day IV continuous infusion on days 1 to 7 (total dose per cycle: 0.7 mg/kg) |
'''7-day course''' | '''7-day course''' | ||
| − | ===Regimen #2 | + | ===Regimen #2, Zenhäusern, et al. 2009=== |
| − | *[[Cladribine (Leustatin)]] 0.14 mg/kg/day IV continuous infusion on days 1 | + | *[[Cladribine (Leustatin)]] 0.14 mg/kg/day IV continuous infusion on days 1 to 5 (total dose per cycle: 0.7 mg/kg) |
'''5-day course''' | '''5-day course''' | ||
| − | ===Regimen #3 | + | ===Regimen #3, Zenhäusern, et al. 2009=== |
| − | *[[Cladribine (Leustatin)]] 0.14 mg/kg/day IV once | + | *[[Cladribine (Leustatin)]] 0.14 mg/kg/day IV once per day on days 1, 8, 15, 22, 29 |
'''5-week course''' | '''5-week course''' | ||
===References=== | ===References=== | ||
| − | # Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005 Jul 1;106(1):241-6. Epub 2005 Mar 10. [http://bloodjournal.hematologylibrary.org/content/106/1/241.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15761021 PubMed] | + | # Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005 Jul 1;106(1):241-6. Epub 2005 Mar 10. [http://bloodjournal.hematologylibrary.org/content/106/1/241.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15761021 PubMed] content property of [http://hemonc.org HemOnc.org] |
# Zenhäusern R, Schmitz SF, Solenthaler M, Heim D, Meyer-Monard S, Hess U, Leoncini L, Bargetzi M, Rufener B, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma. 2009 Sep;50(9):1501-11. doi: 10.1080/10428190903131755. [http://informahealthcare.com/doi/abs/10.1080/10428190903131755 link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19672771 PubMed] | # Zenhäusern R, Schmitz SF, Solenthaler M, Heim D, Meyer-Monard S, Hess U, Leoncini L, Bargetzi M, Rufener B, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma. 2009 Sep;50(9):1501-11. doi: 10.1080/10428190903131755. [http://informahealthcare.com/doi/abs/10.1080/10428190903131755 link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19672771 PubMed] | ||
==Pentostatin (Nipent)== | ==Pentostatin (Nipent)== | ||
| − | ===Regimen=== | + | ===Regimen, Cassileth, et al. 1991=== |
| − | *[[Pentostatin (Nipent)]] 5 mg/m2 IV over 2 minutes once | + | *[[Pentostatin (Nipent)]] 5 mg/m2 IV over 2 minutes once per day on days 1 & 2 |
'''14-day cycles, continued to the point of maximal response or treatment failure''' | '''14-day cycles, continued to the point of maximal response or treatment failure''' | ||
Supportive medications: | Supportive medications: | ||
| − | *Allopurinol (Aloprim) 300 mg PO once | + | *Allopurinol (Aloprim) 300 mg PO once per day in "the initial courses of treatment" for prophylaxis |
===References=== | ===References=== | ||
# Cassileth PA, Cheuvart B, Spiers AS, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol. 1991 Feb;9(2):243-6. [http://jco.ascopubs.org/content/9/2/243.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/1988572 PubMed] | # Cassileth PA, Cheuvart B, Spiers AS, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol. 1991 Feb;9(2):243-6. [http://jco.ascopubs.org/content/9/2/243.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/1988572 PubMed] | ||
Revision as of 06:14, 14 June 2013
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Cladribine (Leustatin)
Regimen #1, Chadha, et al. 2005
- Cladribine (Leustatin) 0.1 mg/kg/day IV continuous infusion on days 1 to 7 (total dose per cycle: 0.7 mg/kg)
7-day course
Regimen #2, Zenhäusern, et al. 2009
- Cladribine (Leustatin) 0.14 mg/kg/day IV continuous infusion on days 1 to 5 (total dose per cycle: 0.7 mg/kg)
5-day course
Regimen #3, Zenhäusern, et al. 2009
- Cladribine (Leustatin) 0.14 mg/kg/day IV once per day on days 1, 8, 15, 22, 29
5-week course
References
- Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005 Jul 1;106(1):241-6. Epub 2005 Mar 10. link to original article contains protocol PubMed content property of HemOnc.org
- Zenhäusern R, Schmitz SF, Solenthaler M, Heim D, Meyer-Monard S, Hess U, Leoncini L, Bargetzi M, Rufener B, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma. 2009 Sep;50(9):1501-11. doi: 10.1080/10428190903131755. link to original article contains protocol PubMed
Pentostatin (Nipent)
Regimen, Cassileth, et al. 1991
- Pentostatin (Nipent) 5 mg/m2 IV over 2 minutes once per day on days 1 & 2
14-day cycles, continued to the point of maximal response or treatment failure
Supportive medications:
- Allopurinol (Aloprim) 300 mg PO once per day in "the initial courses of treatment" for prophylaxis
References
- Cassileth PA, Cheuvart B, Spiers AS, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol. 1991 Feb;9(2):243-6. link to original article contains protocol PubMed